Results 21 to 30 of about 3,026 (154)
Microorganisms, 2023 Clostridioides difficile is considered a nosocomial pathogen that flares up in patients exposed to antibiotic treatment. However, four out of ten patients diagnosed with C.
Leon M. T. Dicks
doaj +1 more source
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
Canadian Journal of Infectious Diseases and Medical Microbiology, 2016 Background. This analysis examined the efficacy of fidaxomicin versus vancomycin in 406 Canadian patients with Clostridium difficile infection (CDI), based on data from 2 randomized, clinical trials. Methods. Patients received fidaxomicin or vancomycin 1.
Christine Lee +6 more
doaj +1 more source
Journal of Health Economics and Outcomes Research, 2015 # Background Clostridium difficile is associated with 20–30% of cases of antibiotic-associated diarrhoea. The incidence of C. difficile infection (CDI) is higher in Ireland than in other countries in Europe, and it is associated with considerable ...
Anke van Engen +6 more
doaj +1 more source
Fidaxomicin: A new fight against clostridium difficile-associated diarrhea
Muller Journal of Medical Sciences and Research, 2014 Clostridium difficile-associated diarrhea (CDAD) occurs commonly as a side effect of broad-spectrum antibiotics. Drugs approved for CDAD are only two of them, metronidazole and vancomycin.
Dick B. S. Brashier +2 more
doaj +1 more source
Antimicrobial Activities of Fidaxomicin [PDF]
Clinical Infectious Diseases, 2012 Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤ 0.001-1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC(90)) of 0.5 μg/mL.
Goldstein, Ellie J. C. +2 more
openaire +2 more sources
Antibiotics, 2022 In 2021, the American College of Gastroenterology (ACG), the Infectious Diseases Society of America in conjunction with the Society for Healthcare Epidemiology of America (IDSA/SHEA), and the European Society of Clinical Microbiology and Infectious ...
Jordan Jones +4 more
doaj +1 more source
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
Clinical Pharmacology: Advances and Applications, 2022 Meredith B Oliver,1 Byron P Vaughn2 1M Health Fairview, Masonic Children’s Hospital, Minneapolis, MN, USA; 2Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, USACorrespondence: Byron P Vaughn, Department ...
Oliver MB, Vaughn BP
doaj
Journal of Microbiology, Immunology and Infection, 2018 Background: Clostridium difficile infection (CDI) is a significant cause of morbidity and mortality in both the acute care setting and the wider healthcare system.
Jing-Wei Cheng +8 more
doaj +1 more source
Novel Fidaxomicin Antibiotics through Site-Selective Catalysis [PDF]
Communications Chemistry, 2020 Fidaxomicin (FDX) is a marketed antibiotic for the treatment Clostridium difficile infections (CDI). Although showing interesting antibacterial properties against many Gram-positive bacteria, the application of this antibiotic is currently limited to treatment of CDI.
David Dailler +4 more
openaire +5 more sources
Going Retro, Going Viral: Experiences and Lessons in Drug Discovery from COVID-19
Molecules, 2022 The severity of the COVID-19 pandemic and the pace of its global spread have motivated researchers to opt for repurposing existing drugs against SARS-CoV-2 rather than discover or develop novel ones.
Bing Wang +4 more
doaj +1 more source